Dietary and nutritional products affect individuals differently based on their genetic predisposition, nutritional lifestyle, exercises habits, and their environments.
More than 50% of clinical trials currently fail due to low efficacy.
Several markers and tests have been introduced in the market for diagnosing cancer types and other diseases.
Preclinical research, when related to molecular biology data analysis, mostly includes statistical analysis to identify significantly differentiated molecules in the phenotypes under study.
Publishing scientific findings in domain-specific journals and announcing them in scientific conferences has become an essential part of today’s research environment.
September 16, 2021
The new version of InSyBio Suite includes InSyBio Pipelines, a new tool for automatizing and optimizing the computational process for identifying biomarkers.
August 11, 2021
Traditionally, prescribed opioid analgesics for treating Chronic Pain can become harmful for the patients and negatively affect their lives.
April 27, 2021
InSyBio has joined the Loyal VC program which includes an initial investment from the Toronto, Canada based international fund and provides InSyBio with access to Loyal VC’s global network of over 400 advisors and experienced entrepreneurs, accelerator leaders, advisors, angels and venture investors.